Key result
Vitiligo was associated with a decreased risk of peripheral vascular disease and pulmonary embolism, but similar risk of MI and stroke.
Why the study?
The risk of cardiovascular diseases among patients with vitiligo remains controversial despite associations with obesity, dyslipidaemia, and metabolic syndrome.
Does vitiligo alter the risk of cardiovascular outcomes including MI, CVA, PVD, and PE compared to matched controls?
Cohort (n=123,326)
Does vitiligo alter the risk of cardiovascular outcomes including MI, CVA, PVD, and PE compared to matched controls?
Vitiligo is not associated with an increased risk of myocardial infarction or stroke, and is unexpectedly associated with a decreased risk of peripheral vascular disease and pulmonary embolism.
Answers are grounded in this paper and cite their sources.
Does not warrant altered CV risk assessment in vitiligo; leaves open potential protective effects on PVD and PE.
While some studies have shown an association of vitiligo with obesity, dyslipidaemia and metabolic syndrome,1, 2 the risk of cardiovascular diseases among patients with vitiligo remains a scope of controversy. This study aimed to investigate the risk of myocardial infarction (MI), cerebrovascular accident (CVA), peripheral vascular disease (PVD) and pulmonary embolism (PE) in patients with vitiligo as compared to control individuals. In addition, we aim to estimate the influence of these cardiovascular conditions on the survival of patients with vitiligo. The current population-based study was designed as a retrospective cohort study that longitudinally followed patients with vitiligo and evaluated the incidence of incident MI, CVA, PVD and PE. The computerised data set of Clalit Health Services (CHS) was the source of this study. Clalit Health Service is Israel's largest health-care maintenance organisation, providing a broad array of private and public health-care services for 5,303,110 enrollees as of April 2023. The different features of the utilised data set are detailed in other publications.3, 4 A total of 123,326 participants were included in this study. Of whom, 20,851 were patients with vitiligo, and 102,475 were age-, sex- and ethnicity-matched controls. The baseline characteristics of the study population are delineated in Table 1. Table 2 demonstrates the univariate risk of cardiovascular outcomes among patients with vitiligo stratified by different demographic strata and the multivariate risk adjusted for confounding factors. Patients with vitiligo had a statistically comparable risk of MI (fully adjusted HR, 0.98; 95% CI, 0.86–1.10; p = 0.700) and CVA (fully adjusted HR, 0.91; 95% CI, 0.79–1.05; p = 0.175) as compared to controls. On the other hand, vitiligo was associated with a statistically decreased risk of PVD (fully adjusted HR, 0.69; 95% CI, 0.53–0.89; p = 0.004) and PE (fully adjusted HR, 0.55; 95% CI, 0.36–0.86; p = 0.008). The last endpoint of the study was to evaluate the influence of these comorbidities on the all-cause mortality of patients with vitiligo. Compared with their counterparts lacking these outcomes, vitiligo patients with CVA (fully adjusted HR, 2.37; 95% CI, 1.82–3.07; p < 0.001), PVD (fully-adjusted HR, 1.87; 95% CI, 1.17–3.00; p = 0.009) and PE (fully-adjusted HR, 4.91; 95% CI, 2.31–10.42; p < 0.001) displayed a significantly elevated risk of all-cause mortality. The presence of MI did not confer an elevated risk of mortality (fully adjusted HR, 1.18; 95% CI, 0.81–1.70; p = 0.393). We then evaluated all-cause mortality among patients with vitiligo and comorbid cardiovascular outcomes relative to controls with these outcomes. Vitiligo patients with comorbid MI (fully adjusted HR, 0.70; 95% CI, 0.60–0.81; p < 0.001) and CVA (fully adjusted HR, 0.72; 95% CI, 0.60–0.86; p < 0.001) demonstrated lower mortality rate relative to control with the same cardiovascular conditions. On the other hand, the all-cause mortality of vitiligo patients with comorbid PVD (fully adjusted HR, 0.82; 95% CI, 0.64–1.04; p = 0.095) and PE (fully adjusted HR, 0.53; 95% CI, 0.27–1.05; p = 0.069) was similar to that of controls with these conditions. In conclusion, this study demonstrated that Israeli patients with vitiligo have a decreased risk of subsequent PE and PVD and a comparable risk of MI and CVA. Vitiligo patients with comorbid PE, CVA and PVD are at increased risk of all-cause mortality than vitiligo patients without these comorbidities. Additional studies investigating these outcomes in other study populations originating from different ethnic backgrounds are necessary. Further research into the shared underlying pathophysiology of vitiligo and CVD is necessary. This epidemiological evidence may have significant implications for physicians managing patients with vitiligo. None. ADC served as an advisor, investigator or speaker for Abbvie, BI, Dexcel Pharma, Janssen, Novartis, Perrigo, Pfizer and Rafa. None of the other authors have any conflicts of interest to declare. The data that support the findings of this study are available from the corresponding author, KK, upon reasonable request.
No takes yet. Share an insight, caveat, or question.
Kridin et al. (2024) conducted a cohort in Vitiligo (n=123,326). Vitiligo vs. Matched controls without vitiligo was evaluated on Myocardial infarction (MI) (HR 0.98, 95% CI 0.86-1.10, p=0.700). Vitiligo was associated with a decreased risk of peripheral vascular disease and pulmonary embolism, but similar risk of MI and stroke.
Synapse has enriched 10 related papers. Consider them for comparative context: